Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Core Insights - Purple Biotech Ltd. has appointed Shai Lankry as Chief Financial Officer, bringing over 20 years of financial leadership in biotech and healthcare [1][2][3] Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance [4] - The company's oncology pipeline includes CM24, NT219, and CAPTN-3, targeting various cancer indications [4] Leadership Background - Shai Lankry has extensive experience in U.S. and European biotech markets, previously serving as CFO for Gamida Cell Ltd. and holding key financial roles at West Pharmaceutical Services and MacroCure Ltd. [3] - Lankry's experience includes leading a U.S. IPO and M&A transactions, which aligns with Purple Biotech's strategic goals [1][3] Pipeline Highlights - CM24 is a humanized monoclonal antibody that blocks CEACAM1, showing promise in a Phase 2 study for pancreatic ductal adenocarcinoma [4] - NT219 is a dual inhibitor that has demonstrated anti-tumor activity in combination with cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck [4] - CAPTN-3 is a preclinical platform of tri-specific antibodies designed to enhance immune response within the tumor microenvironment [4]